

SET YOURSELF
FREE
WITH...



Sitahenz-50/100

Sitagliptin 50 mg and 100 mg Tablets

Sitahenz-M 500/1000

Sitagliptin 50 mg and Metformin (Sustained Release) 500 mg/1000 mg Tablets

Sitahenz-M OD / M OD LS

Sitagliptin 100 mg and Metformin (Sustained Release) 500 mg/1000 mg Tablets

Sitahenz-MQ 500/1000

Sitagliptin 50 mg and Metformin (Quick Release) 500 mg/ 1000 mg Tablets

Sitahenz-50/100

Sitagliptin 50 mg and 100 mg Tablets

Sitahenz-M OD / M OD LS

Sitagliptin 100 mg and Metformin (Sustained Release) 500 mg/1000 mg Tablets

Sitahenz-M 500/1000

Sitagliptin 50 mg and Metformin (Sustained Release) 500 mg/1000 mg Tablets

Sitahenz-MQ 500/1000

Sitagliptin 50 mg and Metformin (Quick Release) 500 mg/1000 mg Tablets

DESCRIPTION:

SITAHENZ Tablet is available in two strengths i.e. Sitagliptin 50 mg & 100 mg

SITAHENZ-M 500,1000 is a film coated Bilayered tablet contains Sitagliptin (50 mg) and Metformin (as sustained release) 500 mg/1000 mg.

SITAHENZ-MOD / MODLS is a film coated Bilayered tablet contains Sitagliptin 100 mg and Metformin (Sustained Release) 500/1000 mg.

SITAHENZ-MQ 500/1000 contains Sitagliptin 50 mg and Metformin (Quick Release) 500 mg/1000 mg Tablet.

INDICATION:

SITAHENZ : Is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

SITAHENZ-M / MQ / MOD / MODLS : Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

MECHANISM OF ACTION:

Sitagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide to facilitate glucose regulation in response to a meal.

Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.

Dosage & Administration:

SITAHENZ: The recommended dose of SITAHENZ is 100 mg once daily or as prescribed by the doctor.

Dose adjustment is needed for moderate to severe renal impairment:

- ❧ eGFR 30-45 ml/min : 50 mg once daily
- ❧ eGFR < 30 ml/min including end stage renal disease on dialysis : 25 mg once daily.

SITAHENZ-M/MQ: The recommended total daily starting dose of SITAHENZ-M/MQ is 100 mg sitagliptin and 1000 mg metformin or as prescribed by the Physician.

- ❧ For patients already being treated with metformin 500 mg twice daily, start with: 50/500 mg; 1 tablet, twice daily
- ❧ For patients already being treated with metformin 850 mg or 1000 mg twice daily, start with: 50/1000 mg; 1 tablet, twice daily

SITAHENZ-M OD / M OD LS: The recommended dose is 100 mg sitagliptin and 500/1000 mg metformin or as prescribed by the Physician.

References:
Drugs Today (Barc). 2007 Jan;43(1):13-25.
Vasc Health Risk Manag . 2008;4(2):383-94.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2022 All rights reserved. La Renon Healthcare Private Limited